NEIMETH INTERNATIONAL PHARMACEUTICALS : QUARTER 2 - FINANCIAL STATEMENT FOR 2022
July 29, 2022 at 06:56 pm
Share
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
FINANCIAL STATEMENTS 30 JUNE 2022
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 JUNE 2022
Contents
Page
Statement of financial position
1
Statement of profit or loss and other comprehensive income
2-3
Statement of changes in equity
4
Statement of cash flows
5
Free Float Assessment
6
Notes to the financial statements
7-47
Other national disclosures:
Statement of value added
46
Financial summary
47
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE PERIOD ENDED 30 JUNE 2022
30-Jun-22
30-Jun-21
Note
N'000
N'000
Turnover
8
1,826,865
1,991,296
Cost of sales
9
(1,103,288)
(1,064,285)
Gross profit / (Loss)
723,577
927,011
Other income
10
18,926
16,638
Marketing and distribution expenses
11
(437,415)
(394,744)
Administrative expenses
12
(412,424)
(346,637)
Exchange Gain / (Loss)
13
94,694
(3,994)
Operating profit
(12,643)
198,274
Finance costs
14
(121,007)
(113,446)
(Loss)/Profit before taxation
(133,652)
84,828
Income tax expense
28
-
-
(Loss)/ Profit for the year from continued operation
(133,652)
84,828
Other comprehensive income
Gain on available for sale assets
-
-
Total other comprehensive income
-
-
Total comprehensive (Loss)/Profit
(133,652)
84,828
Basic (loss)/earnings per share
32
(7)
4
The explanatory notes and statement of significant accounting policies form an integral part of these financial statements.
2
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 JUNE 2022
Quarter 2
YTD
Quarter 2
YTD
Ended
ended
Ended
ended
Apr - June ' 22
30-Jun-22
Apr - June '21
30-Jun-21
Note
N'000
N'000
N'000
N'000
Turnover
8
841,617
1,826,865
709,720
1,991,296
Cost of sales
9
(543,755)
(1,103,288)
(323,076)
(1,064,285)
Gross profit / (Loss)
297,862
723,577
386,644
927,011
Other income
10
6,477
18,926
5,439
16,638
Marketing and distribution expenses
11
(140,818)
(437,415)
(122,626)
(394,744)
Administrative expenses
12
(93,548)
(412,424)
(120,306)
(346,637)
Exchange Gain/ (Loss)
13
91,238
94,694
(21,499)
(3,994)
Operating profit
161,211
(12,643)
127,652
198,274
Finance costs
14
(85,929)
(121,007)
(71,129)
(113,446)
(Loss)/Profit before taxation
75,282
(133,652)
56,523
84,828
Income tax expense
28
-
-
(Loss)/ Profit for the year from continued operation
75,282
(133,652)
56,523
84,828
Other comprehensive income
Gain on available for sale assets
-
-
-
Total other comprehensive income
-
-
-
Total comprehensive (Loss)/Profit
75,282
(133,652)
56,523.00
84,827.96
Basic (loss)/earnings per share
32
3.96
(7.04)
2.98
1,901,866.00
The explanatory notes and statement of significant accounting policies form an integral part of these financial statements.
3
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Neimeth International Pharmaceuticals plc published this content on 29 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 July 2022 17:54:52 UTC.
Neimeth International Pharmaceuticals Plc is engaged in the manufacturing and marketing of pharmaceuticals and animal health products. The Company operates through two segments: Pharmaceuticals product group and Animal health product group. Pharmaceuticals product group is engaged in the marketing and sales of the Company's branded products and the products under the consumer product group. Animal health product group is engaged in the marketing and sales of poultry and animal range of anthelmintics, as well as production medicaments. Its products include Ethical Products, Veterinary Products, and Healthcare Products. Its Ethical Products include Ciklavit, Flucosyd, Amlovar, Co-Amoxiclav, Gyno-Tiocosid, Miniplus, Neimelyn, Norduet, and Normoretic. Veterinary Products include Neimeth Piperazine, Neimycin Soluble Powder, and Neiva Stress. Its Healthcare Products include Antimal, Homtamin G, Urah, Nimartem, and Pancemol. The Company operates in two geographic regions: Nigeria and Ghana.